NCT02966821View on ClinicalTrials.gov

Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

January 3, 2017

Primary Completion Date

August 17, 2018

Study Completion Date

November 30, 2018

Conditions
Biliary Tract Cancer
Interventions
DRUG

Surufatinib

Patients receive oral Surufatinib at a dose of 300mg/d within 1 hour after breakfast (once-daily dosing continuously, every 28-day treatment cycle)

Trial Locations (5)

100032

Peking Union Medical College Hospital, Beijing

100071

The 307th Hospital of Military Chinese People's Liberation Army, Beijing

150040

Heilongjiang Cancer Hospital, Harbin

200032

Shanghai Zhongshan Hospital, Shanghai

300060

Tianjin medical university cancer institute&hospital, Tianjin

All Listed Sponsors
lead

Hutchison Medipharma Limited

INDUSTRY

NCT02966821 - Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma | Biotech Hunter | Biotech Hunter